

# Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine

NCT05962229

---

Status	RECRUITING
Phase	Phase 1
Sponsor	University of California, San Francisco
Enrollment	18 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Healthy on the basis of medical history and limited physical examination.
- Current regular user of E-Cigarettes (e 15 days in the past 30 days)

### Exclusion (12)

- Medications
- Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs).
- Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers).
- Concurrent use of nicotine-containing medications (Example: nicotine patch, lozenge, gum).
- Any stimulant medications (example: Adderall) generally given for ADHD treatment.

... and 7 more (see full listing online)

## Locations (1 total)

---

Zuckerberg San Francisco General Hospital (ZSFG), San Francisco, California, United States